Pharmacogenomics and the Genetic Information Nondiscrimination Act of 2008: Legislation Limitations and Its Impact on PGx Research and Clinical Opportunity by Tessmer, Amanda
Saint Louis University Journal of Health Law & Policy 
Volume 3 
Issue 1 Living in the Genetic Age: New Issues, 
New Challenges 
Article 9 
2009 
Pharmacogenomics and the Genetic Information 
Nondiscrimination Act of 2008: Legislation Limitations and Its 
Impact on PGx Research and Clinical Opportunity 
Amanda Tessmer 
am.tess@gmail.com 
Follow this and additional works at: https://scholarship.law.slu.edu/jhlp 
 Part of the Health Law and Policy Commons 
Recommended Citation 
Amanda Tessmer, Pharmacogenomics and the Genetic Information Nondiscrimination Act of 2008: 
Legislation Limitations and Its Impact on PGx Research and Clinical Opportunity, 3 St. Louis U. J. Health 
L. & Pol'y (2009). 
Available at: https://scholarship.law.slu.edu/jhlp/vol3/iss1/9 
This Student Comment is brought to you for free and open access by Scholarship Commons. It has been accepted 
for inclusion in Saint Louis University Journal of Health Law & Policy by an authorized editor of Scholarship 
Commons. For more information, please contact Susie Lee. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
 
153 
PHARMACOGENOMICS AND THE GENETIC INFORMATION 
NONDISCRIMINATION ACT OF 2008: LEGISLATION LIMITATIONS AND 
ITS IMPACT ON PGx RESEARCH AND CLINICAL OPPORTUNITY 
I.  INTRODUCTION 
Pharmacogenomics (“PGx”) can be defined as “a science that examines 
the inherited variations in genes that dictate drug response and explores the 
ways these variations can be used to predict whether a patient will have a 
good response to a drug, a bad response to a drug, or no response at all.”1  
To be most effective, PGx research requires a large population sample with 
diverse racial, ethnic, and genetic backgrounds.2  However, genetic 
discrimination has become the most commonly cited reason for individuals 
to forgo voluntary research.3  Through the Genetic Information 
Nondiscrimination Act of 2008 (“GINA”), Congress has attempted to 
alleviate this fear by providing a federal law that bans genetic discrimination 
by employers and insurance companies.4 
However, the goal of increasing voluntary participation in PGx research 
may never fully come to fruition because a lack of research participation 
likely reaches far beyond the fear of genetic discrimination.  Numerous 
other psychological and social risks, including fears of interference with 
 
 1. National Center for Biotechnology Information, Just the Facts: A Basic Introduction to 
the Science Underlying NCBI Resources, http://www.ncbi.nlm.nih.gov/About/primer/ 
pharm.html (last visited Mar. 17, 2010). 
 2. See Gail Henderson et al., Great Expectations: Views of Genetic Research Participants 
Regarding Current and Future Genetic Studies, 10 GENETICS MED. 193, 193 (2008). 
 3. See MICHELE SCHOONMAKER & ERIN D. WILLIAMS, GENETIC TESTING: SCIENTIFIC 
BACKGROUND AND NONDISCRIMINATION LEGISLATION 24 (2006) (noting that “fear caused by 
the possibility that a job may be lost or insurance may be cancelled—whether real or 
perceived—is the primary reason individuals refrain from seeking what could be a beneficial 
genetic test in clinical or research settings”); see generally Genetic Information 
Nondiscrimination Act of 2008 (GINA), Pub. L. No. 110–223, § 2, 122 Stat. 881 (2008) (to 
be codified in scattered sections of 26 U.S.C., 29 U.S.C., and 42 U.S.C).  Congress enacted 
GINA after being informed about cases of genetic discrimination.  GINA, 122 Stat. at 882-
83. 
 4. See generally GINA, 122 Stat. at 881-921.  GINA provides uniform federal 
legislation that establishes basic standards aimed “to fully protect the public from 
discrimination and allay their concerns about the potential for discrimination, thereby allowing 
individuals to take advantage of genetic testing, technologies, research, and new therapies.”  
GINA §2, 122 Stat. at 882-83. 
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familial relationships,5 concerns that the individual is better off not knowing 
the results of the genetic test,6 and distrust towards medical research may 
dissuade individuals from participating in research and clinical 
opportunities.7 
While GINA has taken a substantial step forward in protecting 
individuals from genetic discrimination, and thus calming some of the 
American public’s fears, PGx research will only reach its full potential when 
other risks are clearly identified and addressed through public education 
and public participation in the decision-making processes.8  For minority 
participants, community involvement that promotes “engagement, dialogue, 
and feedback” is one approach to better understand the barriers that 
influence minority participation in genetic research.9  Beyond the protections 
ensured by GINA, these community programs may also help to advance the 
emerging scientific field of PGx. 
Sections II and III of this comment focus on the science and underlying 
technology of PGx research, as well as its future goals.  These sections also 
identify several current clinical uses of PGx technology and discuss hurdles 
PGx faces in the coming years.  Section IV discusses the importance of 
including minority populations in PGx research populations and the 
controversy surrounding race as a biological classification.  Section V 
illustrates current obstacles of PGx research, including specific instances of 
genetic discrimination, while section VI addresses failed legislative efforts at 
combating discrimination.  Next, section VII describes pertinent provisions of 
GINA, the most recent non-discrimination effort.  Section VIII analyzes the 
numerous limitations of GINA, including the legislature’s failure to address 
other obstacles to genetic research participation, especially among minority 
populations.  Finally, section IX explains approaches to addressing the 
others barriers of genetic and clinical research, all of which share the goal 
of increasing minority research participation. 
This comment attempts to answer two central issues surrounding PGx: 
First, how does GINA help further the goals of PGx and how is the 
legislation limited in clinical practice?  Second, beyond GINA, what other 
barriers to genetic research need to be addressed so that the future of PGx 
can continue to develop in research and clinical application? 
 
 5. See SCHOONMAKER & WILLIAMS, supra note 3, at 23-24 (noting that, for example, 
some family members may not want to know the results of paternity tests). 
 6. See Henderson et al., supra note 2, at 196. 
 7. Barbara A. Noah, The Participation of Underrepresented Minorities in Clinical 
Research, 29 AM. J.L. & MED. 221, 229-31 (2003). 
 8. See Paul Slovic, Trust, Emotion, Sex, Politics, and Science: Surveying the Risk 
Assessment Battlefield, 1997 U. CHI. LEGAL F. 59, 95–96 (1997). 
 9. See Giselle Corbie-Smith et al., Distrust, Race, and Research, 162 ARCHIVES INTERNAL 
MED. 2458, 2462 (2002). 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2009] PHARMACOGENOMICS AND GINA 155 
II.  PHARMACOGENOMICS: HISTORY AND BASIC SCIENCE 
PGx aims to “identify and quantify the association between variations in 
DNA sequence and variations in the drug response phenotype (i.e. the 
‘genotype-phenotype correlation’).”10  The study of PGx merges the fields of 
pharmacology, genetics, and human genomics.11  The research goals of 
PGx are focused on defining drug absorption, drug safety, and drug efficacy 
for a particular genotype in order to move from the current “one size fits all” 
standard for prescription drugs, to a more precise “personalized drug” 
standard.12  In doing so, the pharmaceutical industry hopes to reduce, if not 
eliminate, adverse drug reactions (“ADRs”).13 
The underlying science of PGx, although relatively new to most 
physicians and patients, has been studied since the early 1900s.14  In 1902, 
Archibald Garrod theorized that alcaptonuria was caused by a genetic 
variation in the metabolic pathway that broke down toxic substances in the 
body.15  Later, during World War II, specific drug reactions based on 
inherited genetic variations were recorded for the first time.16  Then in 1959 
the term “pharmacogenetics” was first used by Fredrich Vogel.17  Even 
though the two terms are sometimes used interchangeably in the literature, 
“pharmacogenetics is generally recognized as the study of how individual 
genetic differences affect drug response [whereas] pharmacogenomics 
encompasses the role of the whole genome in pharmacology and drug 
design.”18 
 
 10. DEP’T OF HEALTH & HUMAN SERV., SECRETARY’S ADVISORY COMM. ON GENETICS, HEALTH, 
& SOCIETY, REALIZING THE POTENTIAL OF PHARMACOGENOMICS: OPPORTUNITIES AND CHALLENGES 
14 (2008) [hereinafter HHS]. 
 11. Id. at 9. 
 12. O. P. Corrigan, Pharmacogenetics, Ethical Issues: Review of the Nuffield Council on 
Bioethics Report, 31 J. MED. ETHICS 144, 144–45 (2005).  See also Lawrence J. Lesko et al., 
Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision 
Making: Report of the First FDA-PWG-PhRMA-DruSafe Workshop, 43 J. CLINICAL 
PHARMACOLOGY 342, 343 (2003). 
 13. Corrigan, supra note 12, at 145. 
 14. See Berrie Rebecca Goldman, Pharmacogenomics: Privacy in the Era of Personalized 
Medicine, 4 NW. J. TECH. & INTELL. PROP. 83, 85 (2005). 
 15. Penelope K. Manasco & Teresa E. Arledge, Drug Development Strategies, in 
PHARMACOGENOMICS: SOCIAL, ETHICAL, AND CLINICAL DIMENSIONS 83, 89 (Mark A. Rothstein 
ed., 2003). 
 16. See Goldman, supra note 14, at 86 (noting that during World War II, some soldiers 
who were treated with an anti-malarial medication developed anemia due to an underlying 
genetic deficiency of the glucose-6-phosphate dehydrogenase enzyme). 
 17. Barbara Ann Binzak, How Pharmacogenomics Will Impact the Federal Regulation of 
Clinical Trial and the New Drug Approval Process, 58 FOOD & DRUG L.J. 103, 104 (2003). 
 18. HHS, supra note 10, at 9.  Pharmacogenomics can be further defined as “the study of 
how individual genetic differences affect drug response . . . This definition encompasses 
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Today, the Human Genome Project (“HGP”), spearheaded by the 
Department of Energy (“DOE”) and the National Institutes of Health (“NIH”), 
has helped advance the field of PGx through the identification of 
approximately 25,000 genes in human DNA.19  “More than 1.4 million 
single-nucleotide polymorphisms [SNPs] were identified in the initial 
sequencing of the human genome, with over 60,000 of them in the coding 
region of genes.”20  Individualized PGx information is gathered through 
comparing an individual’s single nucleotide sequence to the nucleotide 
sequence that was discovered from the HGP to see if the DNA “matches” 
the normal sequence.21  Because SNPs may affect drug-metabolizing 
enzymes, understanding SNPs will be an important tool in predicting an 
individual’s response to certain medications.22  The ultimate aim is that 
physicians will use an individual’s genotype to determine which drugs and 
dosages have been shown to be safe and effective through clinical drug 
trials that utilized PGx data.23  Likewise, those individuals without the 
requisite genotype will be able to forgo unnecessary and possibly unsafe 
treatment.24  PGx aims to bring previously rejected drugs into the market 
place by making them safe for a genetically targeted population,25 and also 
to introduce newly formulated drugs that target specific genotypes.26  
Therefore, PGx will change the pharmaceutical industry’s approaches to 
drug development, clinical trials, and marketing.27  In return, it is predicted 
 
interindividual genetic differences such as variation in [DNA] sequence, gene expression, and 
copy number related to an individual’s metabolism of drugs (pharmacokinetics) or . . . 
physiological response to drugs (pharmacodynamics).”  Id. at 9-10.  For the purpose of this 
comment, pharmacogenomics and pharmacogenetics are used interchangeably and denoted 
by the short-form PGx. 
 19. Binzak, supra note 17, at 109; William E. Evans & Howard L. McLeod, 
Pharmacogenomics—Drug Disposition, Drug Targets, and Side Effects, 348 NEW ENG. J. MED. 
538, 538 (2003). 
 20. Evans & McLeod, supra note 19, at 538.  See also Biznak, supra note 17, at 109. 
 21. See Binzak, supra note 17, at 109. 
 22. Id. at 110. 
 23. Teresa Kelton, Pharmacogenomics: The Rediscovery of the Concept of Tailored Drug 
Therapy and Personalized Medicine, HEALTH LAW., Jan. 2007, at 1, 3. 
 24. Id. 
 25. Alan Dove, Pharmacogenomics Regulations Take Flight, DRUG DISCOVERY & DEV., Jan. 
2006, at 40, 41. 
 26. See HHS, supra note 10, at 28. 
 27. See Binzak, supra note 17, at 113 (discussing that PGx will change the 
pharmaceutical industry by allowing companies to identify a new drug compound that will 
interact with a person based on genotype, “saving” drugs that had previously been rejected by 
the FDA, using diagnostic tests in drug trials for drugs that have already been approved, and 
performing follow-up trials on specific subpopulations as ADRs are reported). 
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that PGx could save the industry $300 million a year and each drug will 
take two fewer years to develop.28 
III.  CLINICAL DRUG DEVELOPMENT, PGX RESEARCH, AND CLINICAL OPPORTUNITY 
Currently, physicians engage in a “trial and error” approach when 
determining what drugs to prescribe to their patients.29  The goal is always 
to find a safe and effective drug; however this goal may be thwarted by side 
effects and ADRs.30  “Although ADRs can result from a variety of factors, 
genetic variations of drug-metabolizing enzymes have been highly 
correlated with ADRs in some instances.”31  ADRs pose extreme risks to 
patients; more than two million serious adverse events occur each year, 
resulting in more than 135,000 deaths.32  Patients that are hospitalized due 
to ADRs face an average of 1.7–2.2 days in the hospital and between 
$2,000 and $2,600 in medical care costs.33  Further, ADRs are the primary 
reason medications are withdrawn from the market.34 
The trial-and-error approach also causes physicians to prescribe an 
estimated three million incorrect or ineffective medications every year.35  
Currently, there is no trial and error drug that is 100 percent safe and 
effective for use with 100 percent of the population.  Partially as a result of 
ineffectiveness, patients with chronic conditions, for example, often do not 
follow through with their medication treatment.36 
The first step in attempting to curtail the trial and error approach of 
prescribing medication is to gather PGx data for clinical drug trial 
participants.  During Phase I trials, a small population of healthy individuals 
are studied to identify their tolerability to investigative drugs, which helps 
determine associated ADRs and how drugs should be dosed.37  Next, Phase 
II trials include several hundred to a thousand subjects who have the disease 
that the investigative drug seeks to treat.38  During this phase, PGx data can 
be used to identify a correlation between the safety and efficacy of the drug 
 
 28. Id. 
 29. Kelton, supra note 23, at 1. 
 30. Id. 
 31. See HHS, supra note 10, at 11; see also Biznak, supra note 17, at 110 (noting that 
CYP3A, a drug metabolizing enzyme, is involved in the breakdown of up to fifty percent of 
clinically therapeutic agents). 
 32. Kelton, supra note 23, at 6. 
 33. Id. 
 34. HHS, supra note 10, at 11. 
 35. Id. 
 36. Id., at 12-13 (noting that “[h]alf of patients with chronic health conditions discontinue 
their medications after 1 year”). 
 37. See Manasco & Arledge, supra note 15, at 89. 
 38. Id. at 90. 
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and the genotypic variations that may explain ineffective or unsafe 
reactions.39  Further, this type of PGx data can later be used to develop 
commercial tests that identify the variation in patients.40  Finally, during 
Phase III trials, PGx data can be used to identify more stringent inclusion 
and exclusion participation criteria.41  This hopefully will reduce the 
population size, make the trial more effective (because all of the participants 
will or will not have the particular genetic variation that reacts with the 
drug), and decrease research costs.  Drugs developed with PGx data will not 
be 100 percent effective, nor will they have zero incidence of ADRs.  
However, PGx drugs will be marketed specifically to those patients who have 
the genotype that reacts to the particular drug, and in doing so, will 
presumably make drugs on the market more safe and effective. 
With regard to drug labeling, by using drug labels to warn patients of 
risks to specific genotypes and by requiring genetic tests prior to drug 
treatment, pharmaceutical companies may be able to reduce their liability 
and avoid lawsuits.42  This seems practical given the relative ease of SNP 
genotyping.43  However, the most recent data indicates that only 121 drug 
labels (out of 1200 drug labels reviewed) contained pharmacogenomic 
information.44  Even though PGx data is available for seventy-one percent of 
the top 200 prescribed drugs, only three actually contain package inserts.45  
Federal law requires that certain information should be included in the 
indications and usage section of the drug label “[i]f evidence is available to 
support the safety and effectiveness of the drug only in selected subgroups 
of the larger population . . .” 46 or “[i]f specific tests are [needed] for 
 
 39. Id. 
 40. Id. at 91. 
 41. See id. 
 42. See, e.g., Binzak, supra note 17, at 107 (discussing lawsuits brought against 
SmithKline Beecham claiming that LYMErix vaccine should have been labeled to indicate a 
possible ADR for people with the HLA-DR4+ genotype). 
 43. See David J. Wu, A Pharmacogenomics Standard for FDA Drug Approval: Arbitrary 
and Capricious or Safe and Effective?, 23 BIOTECH. L. REP. 733, 738 (2004) (stating an 
individual’s genotype, and thus any variant SNP, can be determined within “minutes rather 
than hours or days”). 
 44. See Felix W. Frueh et al., Pharmacogenomic Biomarker Information in Drug Labels 
Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use, 
28 PHARMACOTHERAPY 992, 994 (2008). 
 45. HHS, supra note 10, at 76 (citing Issam Zineh et al., Discordance Between Availability 
of Pharmacogenetics Studies and Pharmacogenetics-Based Prescribing Information for the Top 
200 Drugs, 40 ANNALS PHARMACOTHERAPY 639, 639 (2006) (stating that “pharmacogenetics 
data are available in only about 2% of all drug package inserts (PIs) and that less than 1% of 
PIs have pharmacogenetics data sufficient to guide therapy”)). 
 46. 21 C.F.R. § 201.57(c)(3)(i) (2006). 
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selection or monitoring of the patients who need the drug.”47  Undoubtedly, 
this may include data gathered through PGx research. 
Recently, the FDA approved Herceptin®, making it the first drug to be 
approved based upon PGx data.48  It was approved for patients with breast 
cancer who over-express the HER-2/neu protein.49  The label now advises 
patients to undergo a genetic test prior to taking the medication, 
“HERCEPTIN should only be used in patients whose tumors have HER2 
protein overexpression [sic].”50  Ideally, through PGx data, researchers will 
be able to specifically pinpoint the type of genotypic variations that cause 
some types of ADRs, and address them on the drug label. 
The clinical applications of PGx research in diagnostic testing have thus 
far been limited.51 
The decision of whether a pharmacogenetic and pharmacogenomic test is 
necessary prior to dosing will be dependent on many factors, including the 
following: (1) if safety, the seriousness of the adverse event; (2) if efficacy, 
the consequences of nonresponse; (3) the incidence of the clinical outcome; 
(4) the variability in the clearance of the drug; (5) how well an adverse event 
can be managed . . . (6) need for education of physicians and third-party 
payers; and (7) feasibility of accessing and using the test in clinical 
practice.52 
Regardless of clinical applications, research on Cytochrome p450 
(“CYP450”) has already proven to be important.53  CYP450 is a protein that 
metabolizes more than twenty-five percent of all prescription drugs.54  
Mutations in the CYP450 genes cause certain drugs to metabolize at 
drastically different rates.55  This results in a less effective and more 
dangerous drug because some patients will not be able to eliminate the 
medication, which may become toxic to the body.56  On the other hand, if 
drugs are eliminated from the body too quickly they may not have any 
physiological response.  Consequently, in 2004, the AmpliChip® 
 
 47. 21 C.F.R. § 201.57. 
 48. Kelton, supra note 23, at 5. 
 49. GENENTECH, INC., HERCEPTIN® (2000) (package insert), available at http://www.fda. 
gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/A
pprovalApplications/TherapeuticBiologicApplications/ucm092760.pdf. 
 50. Id. 
 51. See HHS, supra note 10, at 17. 
 52. See Lesko, supra note 12, at 351. 
 53. See HHS, supra note 10, at 11. 
 54. See Kelton, supra note 23, at 5. 
 55. Id. 
 56. See Yusuke Nakamura, Pharmacogenomics and Drug Toxicity, 359 NEW ENG. J. MED. 
856, 857 (2008); Kelton, supra note 23, at 5. 
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Cytochrome p450 Genotyping Screening Test was designed.57  The test 
detects mutations in two CYP450 genes58 allowing a physician to determine 
the right drug dose for the patient based on how the patient’s body 
expresses CYP450.59  Over half of all drug labels available with PGx data 
reference CYP2D6 or CYP2C19.60 
Particularly, the CYP2D6 enzyme is involved in metabolizing seventy-five 
percent of all psychotropic drugs.61  One such drug, risperidone, is poorly 
metabolized in seven percent of Caucasians and one to two percent of other 
races.62  Such a deficiency, if gone unidentified, can cause severe ADRs.63  
An example of this reaction is found in the case of Michael Conroy-Adams, 
a nine-year old boy who was prescribed Prozac.64  Michael had a genetic 
variation on the CYP2D6 receptor that caused his body to metabolize the 
drug slowly.65  Sadly, this led to a fatal accumulation of toxic substances in 
his body.66  If a genetic test had been done prior to his prescription, instead 
of during an autopsy, the variant may have been discovered and Michael 
may still be alive. 
Similarly, the CYP2C19 enzyme metabolizes warfarin, a drug prescribed 
for people at risk for blood clots that works by blocking the Vitamin K 
pathway.67  Individuals whose genotypes are homozygous for the *3 allele 
of the gene are slow metabolizers of warfarin and do not clear the drug 
properly.68  This results in a toxic buildup of the drug that can lead to an 
ADR.69  Therefore, the identification of the CYP450 gene, its variants, and 
its associated SNPs, make it clear that genetic tests developed through PGx 
research can be life-saving. 
 
 57. Id. 
 58. Id. 
 59. See generally Wu, supra note 43, at 745 (arguing that FDA should require 
mandatory genetic testing and data submission for CYP450 genes because they are highly 
polymorphic and metabolize a large percentage of drugs at possibly different rates). 
 60. See Frueh, supra note 44, at 995. 
 61. See John Bray et al., 15 J. PSYCHIATRIC & MENTAL HEALTH NURSING 357, 358 (2008).  
CYP450 enzymes are also responsible for metabolizing Adderall®, Coreg®, Effexor®, 
Inderal®, Paxil®, Prozac®, Strattera®, Toprol®, Tussionex®, and Zofran®.  HHS, supra 
note 10, at 11. 
 62. See Bray, supra note 61, at 358. 
 63. Id. 
 64. Wu, supra note 43, at 733. 
 65. Id. 
 66. Id. 
 67. See Evgeny Krynetskiy & Patrick McDonnell, Building Individualized Medicine: 
Prevention of Adverse Reactions to Warfarin Therapy, 322 J. PHARMACOLOGY & EXPERIMENTAL 
THERAPEUTICS 427, 428 (2007). 
 68. HHS, supra note 10, at 15. 
 69. See Krynetskiy & McDonnell, supra note 67, at 428. 
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Another current application of PGx concerns a genetic test that 
determines whether or not patients have an inherited variation in the enzyme 
thiopurine methyltransferase (“TPMT”) which metabolizes a drug used to 
treat acute lymphoblastic leukemia in children.70  Children who have a 
germline variation do not metabolize the drug as quickly or effectively as 
those without the variation.71  This results in toxic levels of the drug in the 
bloodstream, inevitably leading to destruction of bone marrow and possibly 
death.72  When children are tested for the TPMT variation, their physicians 
can better determine the appropriate course of treatment, type of drug, and 
necessary dosage.  Such a test will hopefully result in less pain and suffering 
for children with acute lymphoblastic leukemia. 
The FDA may be partially to blame for the low utilization of PGx 
research and application.  The FDA issued guidance documents for 
submitting PGx data in investigational new drug applications (“INDs”) in 
March, 2005.73  These guidance documents amount to nothing more than 
suggestions for the pharmaceutical industry to follow, and as such, are 
completely voluntary.74  If the FDA made PGx data a requirement rather 
than a recommendation, the pharmaceutical industry would have no choice 
but to include PGx research in clinical drug trials.75  Indirectly, the 
requirements may result in package inserts, drug labels, and diagnostic 
genetic tests indicating safety and efficacy based on PGx data.  In this 
regard, some argue that the FDA is not doing enough to keep patients safe 
even though it possesses the authority to do so.76 
IV.  PGX AND MINORITY POPULATIONS 
Throughout drug development, PGx data will be useful in defining the 
precise genotypes that are likely to respond to specific drugs in a certain 
way.77  Because genetic SNPs can vary between racial groups, a widely 
diverse population sample during clinical drug trials will be necessary to 
realize the full potential of PGx.78  As discussed with the CYP2D6 enzyme, 
 
 70. HHS, supra note 10, at 14. 
 71. Id. at 14-15. 
 72. Id. 
 73. DEP’T OF HEALTH & HUMAN SERV., FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: 
PHARMACOGENOMIC DATA (2005), http://www.fda.gov/downloads/RegulatoryInformation/ 
Guidances/UCM126957.pdf. 
 74. Id. at 1. 
 75. See Dove, supra note 25, at 42. 
 76. See Wu, supra note 43, at 734. 
 77. HHS, supra note 10, at 23. 
 78. See Osagie K. Obasogie, Beyond Best Practices: Strict Scrutiny as a Regulatory Model 
for Race-Specific Medicines, 36 J.L. MED. & ETHICS 491, 492 (2008) (discussing that genetic 
variants which appear at a frequency of less than twenty percent in a racial group are likely to 
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the way in which individuals metabolize a drug can differ widely between 
racial and ethnic subpopulations, thus affecting drug safety and efficacy.79  
Since genotypic variation exists between racially and ethnically diverse 
populations, gathering enough research data to implement population-wide 
application poses a significant hurdle to PGx research and its application. 
BiDil® is a modern example of PGx research benefitting a racially 
diverse population.  BiDil, patented and marketed by NitroMed, was 
approved by the FDA in 2005 to treat heart disease in African Americans.80  
BiDil has been in existence in one form or another since 1980, when trials 
were first conducted on the drug.81  The drug’s medical use was largely 
discovered by the African-American Heart Failure Trial (A-HeFT), which 
enrolled 1,050 self-identified African-American participants.82  The trial 
found that the placebo group showed a higher rate of mortality and a lower 
quality of life.83  BiDil was shown to reduce death rates in heart failure 
patients by forty-three percent.84  Based on this data, NitroMed ended the 
trail early because it was determined it would be unethical to continue 
 
be contained within that group; Africans have several low-frequency genetic variants and thus, 
genetic variants are common and contained within the group). 
 79. See Bray, supra note 61, at 358 (discussing that the incidence of poor metabolism of 
CYP2C19 ranges from fifteen to one hundred percent in certain Asian subgroups and only 
three to six percent in Caucasians); Vural Ozdemir et al., Race as a Variable in 
Pharmacogenomics Science: From Empirical Ethics to Publication Standards, 18 
PHARMACOGENETICS & GENOMICS 837, 837 (2008) (discussing that there is an “unequal 
distribution of disease-associated alleles for certain recessive disorders such as Tay-Sachs 
disease and sickle cell anemia among racially defined populations”); HHS, supra note 10, at 
46 (discussing a Washington, D.C. area study that found two percent of Ashkenazi Jews in the 
area carried mutations in their BRCA 1 and BRCA 2 genes, conferring an increased risk of 
breast and ovarian cancer by age 70). 
 80. Obasogie, supra note 78, at 493.  See also Stephanie Saul, F.D.A. Approves a Heart 
Drug for African Americans, N.Y. TIMES, June 24, 2005 (discussing that BiDil is thought to 
work by increasing levels of nitric oxide in the body, which is more often deficient in African 
Americans, thereby relaxing blood vessels and making it easier for the heart to pump blood), 
available at www.nytimes.com/2005/06/24/health/24drugs.html?_r=1&scp=1&sq=F.D.A.. 
%20Approves%20a%20Heart%20Drug%20for%20African%20Americans&st=cse. 
 81. See generally Sharona Hoffman, “Racially-Tailored” Medicine Unraveled, 55 AM. U. 
L. REV. 395, 400-01 (2005-06).  BiDil consists of a combination of two drugs, hydralazine 
and isosorbide dinitrate.  Id. at 400.  The first studies on the drugs ran from 1980 to 1991 
during the Vasodilator Heart Failure Trials.  Id. at 401.  The trials included black and white 
participants but did not report racial distinctions in drug response rates.  Id. 
 82. Obasogie, supra note 78, at 493. 
 83. Id. 
 84. See Saul, supra note 80. 
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giving the control group a placebo while the other group was benefitting 
substantially from the drug.85 
“Race-based medicine,” as it has become known, is not without 
controversy.86  Some social scientists denounce the use of race as a factor 
for genetic based research.  They argue that race-based research lends itself 
to race stigmatization, stereotyping, and more racial disparity, over forty 
years after the Civil Rights movement.87  Race-based medicines are 
controversial, with Bidil serving as a prime example.88  Generally, critics are 
concerned that pharmaceutical companies and researchers will begin to use 
race as a substitute for genotyping and that race will be used as a 
genetically-based categorization.89  Critics argue that such categorization is 
unfair. “Race, at the continental level, has not been shown to provide a 
useful categorization of genetic information about the response to drugs, 
diagnosis, or causes of disease.”90  However, as the approval of BiDil has 
shown, race-based medicine has advantages and therefore needs research 
participant support in order to further understand genetic differences among 
races.  The effect of such genetic research on various races and ethnicities 
may ensure that medical therapy and PGx will better suit the general 
population.91 
V.  OBSTACLES: CONSENT, PRIVACY, AND GENETIC DISCRIMINATION 
PGx faces numerous obstacles in the years and decades that lie ahead.  
When participants engage in PGx research, they effectively give permission 
for their genetic information to be used in numerous ways, some of which 
 
 85. See Andrew Pollack, Drug Approved for Heart Failure in Black Patients, N.Y. TIMES, 
July 20, 2004, at C1. 
 86. See Obasogie, supra note 78, at 491 (noting that there is a “heated debate in 
scientific and bioethical communities over when and how race should be used in biomedical 
research”). 
 87. See generally Dorothy E. Roberts, Is Race-Based Medicine Good for Us?: African 
American Approaches to Race, Biomedicine, and Equality, 36 J.L. MED. & ETHICS 537, 537 
(noting that there are several different approaches to race-based medicine). 
 88. See generally Hoffman, supra note 81, at 405-06 (discussing that critics of BiDil 
argue that the trial results are not significant because the treatment combination was only 
studied in self-identified African Americans, and therefore it would be erroneous to conclude 
that the treatment is effective only in that population). 
 89. See Saul, supra note 80. 
 90. Richard S. Cooper et al., Race and Genomics, 348 NEW ENG. J. MED. 1166, 1168 
(2003). 
 91. See Alastair J.J. Wood, Racial Differences in the Response to Drugs—Pointers to 
Genetic Differences, 344 NEW ENG. J. MED. 1393, 1394-95 (2001) (arguing that genetic 
differences among racial groups support the use of race-based genetics in medical research 
and drug therapy). 
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are not known at the time of consent.92  The patient/participant, as with any 
medical procedure, must give complete informed consent without 
coercion.93  However, when PGx testing is required for treatment, patients 
may believe that they have to submit their genetic fingerprint in order to 
have their medical needs met.94  Consenting to genetic research has the 
potential to forever link participants to the results of the research by way of 
their genetic profiles.  Because people can be easily identified by only a few 
SNPs, privacy is a continuous issue.95  Consent and privacy are implicated 
even further when a genotyping test implies a risk for future disease, which 
may lead to unintended consequences, such as stigmatization for the patient 
and his or her family.96 
Another commonly cited hurdle to reaching the full potential of PGx is 
the fear that patients’ genetic information will be misused.97  Patients may 
fear that if a genotyping test reveals a genetic disease, they or their family 
members will be discriminated against by insurance companies and 
employers.98  The effect could be a reluctance to submit to PGx clinical 
research for drug development and treatment.  Historically, some form of 
genetic discrimination has occurred in the United States since at least the 
early 1900’s.  During this time, states enacted laws requiring people with 
physical and mental handicaps to undergo sterilization so that they were not 
able to reproduce.99  Indiana was the first state to do so in 1907.100  While 
states have since enacted laws abolishing and repealing state sterilization 
laws,101 perceived and actual genetic discrimination persists. 
Today, genetic discrimination occurs primarily with employment and 
medical insurance.  For employers, the rationale for such discrimination is 
simple; not hiring, firing, or not promoting a person with a genetic 
predisposition to a disease reduces labor and medical expenses.102  
 
 92. See Corrigan, supra note 12, at 146 (noting that patients agree to the participating in 
the clinical drug trial, a genetic test pertaining to the drug effect, and other genetic tests to be 
used in future PGx studies). 
 93. See id. 
 94. See HHS, supra note 10, at 42. 
 95. Id. at 41. 
 96. Wu, supra note 43, at 745.  See GINA, Pub. L. No. 110-223, § 2, 122 Stat. 881, 
882 (2008) (discussing how state-imposed mandatory testing of African Americans for sickle 
cell disease in the 1970s led to discrimination and fear). 
 97. GINA § 2,122 Stat. at 881-82. 
 98. See Goldman, supra note 14, at 83. 
 99. See GINA § 2, 122 Stat. at 882. 
 100. GINA § 2, 122 Stat. at 882. 
 101. GINA § 2, 122 Stat. at 882. 
 102. See COUNCIL FOR RESPONSIBLE GENETICS, GENETIC DISCRIMINATION: POSITION PAPER 
(2001) [hereinafter CRG], http://www.councilforresponsiblegenetics.org/pageDocuments/2R 
SW5M2HJ2.pdf. 
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Specifically, if the employee becomes sick, he or she is likely to be less 
productive, absent from work more often, and have higher insurance 
costs.103  Similarly, the insurance industry operates on reducing risk in order 
to lower benefit payments.104  Naturally, reducing the number of insureds 
who have a greater chance of becoming sick in the future is a way for the 
insurance industry to meet this goal.105 
Americans seem to understand the positive future impact of genetic 
testing, and particularly, PGx.  In 2007, the Genetics and Public Policy 
Center at John Hopkins University completed a survey highlighting 
Americans’ attitudes toward genetic testing.106  The survey found that “more 
than 90 percent support the use of genetic testing by researchers to find new 
ways to diagnose, prevent or treat diseases.”107  Further, “more than 90 
percent of Americans support the use of genetic testing by doctors to identify 
a person’s risk for future disease when there are treatments or medicines 
available, or to determine the risk of having a bad reaction to a particular 
medicine.”108  However, eighty-one percent oppose the use of genetic 
testing by employers “to make decisions about hiring and promotion” and 
eighty-five percent oppose the use of genetic testing by health insurers “to 
determine who [sic] to insure or how much to charge.”109  These statements 
reflect the fear that information can be used adversely by employers and 
insurance companies, which may result in a decision to forego participating 
in genetic research and testing.110 
Despite assertions that genetic discrimination does not occur, others 
argue it is a reality and is significantly underreported due, in part, to low 
utilization of genetic testing, fear of adverse insurance and employment 
actions, and privacy concerns.111  The Council for Responsible Genetics has 
 
 103. Id. 
 104. See id. 
 105. See id. 
 106. See The Genetic Nondiscrimination Act: Hearing on H.R. 493 Before the Subcomm. 
on Health of the H. Energy and Commerce Comm., 110th Cong. 3 (2007) [hereinafter 
Hearing] (testimony of Kathy Hudson, Ph.D., Director, Genetics and Public Policy Center, John 
Hopkins University). 
 107. Id. 
 108. Id. 
 109. Id. at 5. 
 110. See Lauren J. Sismondo, GINA, What Could You Do for Me One Day?: The Potential 
of the Genetic Information Nondiscrimination Act to Protect the American Public, 21 WASH. U. 
J.L. & POL’Y 459, 462 (2006) (discussing that fear of misuse of genetic information stems 
partially from the fact that genetic information is important to “relatives, employers, insurers, 
researchers, and the government”). 
 111. See Karen H. Rothenberg & Sharon F. Terry, Before It’s Too Late—Addressing Fear of 
Genetic Information, 297 SCIENCE 196, 196-97 (2002); see generally Jill Gaulding, Note, 
Race, Sex, and Genetic Discrimination in Insurance: What’s Fair?, 80 CORNELL L. REV. 1646, 
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documented a wide range of cases of employment and insurance 
discrimination.112  In one case, a social worker mentioned during an 
informal conversation at work that her mother died of Huntington’s disease 
and that she had a fifty percent chance of developing the condition.113  One 
week later, the social worker was fired from her job even though her 
performance was well above average.114  With the tremendous amount of 
personal and sensitive information that can be determined from a genetic 
test, the importance of protecting patients and research subjects is 
irrefutable. 
While no per se genetic discrimination case has been decided in the 
United States, several have been filed under various legal theories, and 
others have implicated such discrimination.115  In Norman-Bloodsaw v. 
Lawrence Berkeley Laboratory, former employees of a government-run 
research institute brought a lawsuit under Title VII of the Civil Rights Act and 
the Americans with Disabilities Act (ADA).116  They alleged several violations 
arising from employment entrance examination requirements to submit to 
testing for sickle cell disease, syphilis, and pregnancy.117  In ruling on behalf 
of the former employees, the court noted that “[o]ne can think of few subject 
areas more personal and more likely to implicate privacy interests than that 
of one’s health or genetic make-up.”118  The court went on to state that the 
types of information revealed from these tests were more personal than 
other general medical information and enjoy “the highest expectations of 
privacy.”119  Specifically, the court determined that carrying the sickle cell 
trait has implications of family history and reproductive decisions, and may 
not be necessary for a routine physical examination.120 
 
1665-66 (1995).  Gaulding claims that insurers practice “fair discrimination” when they use 
predictive genetic tests in underwriting because it is the best indication of an insured’s 
expected loss.  Id. at 1665.  For example, any person that tests positive for the Huntington’s 
Disease genetic marker will develop the disease.  Id. at 1666. 
 112. CRG, supra note 102. 
 113. Id. 
 114. Id.  Other cases include: 1) A seven-year-old boy whose genetic test reveals that he 
has a predisposition to a heart disorder was denied insurance on the basis that the genetic 
condition qualifies as a preexisting condition; 2) a young boy with Fragile X Syndrome lost his 
insurance coverage on the basis that his disability represents a preexisting condition; and 3) a 
woman chose not to undergo a BRAC-1 breast cancer screening because she was afraid that 
it would jeopardize her chances of getting a promotion.  Id. 
 115. See Sismondo, supra note 110, at 474-75. 
 116. Norman-Bloodsaw v. Lawrence Berkeley Lab., 135 F.3d 1260, 1264 (9th Cir. 1998). 
 117. Id. at 1264-65. 
 118. Id. at 1269. 
 119. Id. at 1270. 
 120. Id. 
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Similarly, in E.E.O.C. v. Burlington Northern and Santa Fe Railway 
Company, the Equal Employment Opportunity Commission brought a 
lawsuit on behalf of current or former Burlington Northern employees 
alleging genetic discrimination under 42 U.S.C § 12112(d) and § 12203 of 
Title I of the ADA.121  The employees who filed suit alleged that they had 
been forced to submit to a blood test in order to locate a genetic marker for 
carpal tunnel syndrome.122  Further, they alleged that Burlington Northern 
imposed negative consequences for those employees who refused to submit 
to the test.123  Burlington Northern agreed to settle and the court ordered 
that it pay up to $1,775,000 to the employees.124  Burlington Northern also 
agreed to return the genetic samples to the employees.125  Burlington 
Northern’s motive was possibly driven by cost; in the year that the case was 
filed, Burlington Northern received approximately 125 disability claims from 
employees for work-related carpal tunnel syndrome.126 
In addition to a claim under the ADA, the plaintiff in Fleming v. State 
University of New York also alleged a Fourteenth Amendment constitutional 
claim arguing genetic discrimination in violation of due process 
protections.127  The plaintiff stated that he voluntarily disclosed his sickle cell 
disease to his supervisor after hospitalization.128  Roughly three years later, 
the plaintiff applied to and was hired by Yuma Regional Medical Center 
(“Yuma”).129  During its credentialing process, the plaintiff claims Yuma 
contacted the plaintiff’s supervisors who informed Yuma that the plaintiff 
had sickle cell disease.130  The plaintiff claims Yuma questioned him on his 
health and asked why he had not disclosed the information to them 
directly.131  The plaintiff refused to sign an addendum to his employment 
contract, and he believes that such an addendum was part of constructive 
termination.132  In finding that the defendants violated the plaintiff’s right to 
 
 121. EEOC v. Burlington N. & Santa Fe Ry. Co., No. 02-C-0456, 2002 WL 32155386, at 
*1 (E.D. Wis. 2002). 
 122. Id. 
 123. Id. 
 124. Id. at *2. 
 125. See id. at *3.  Burlington Northern agreed to not 1) require its current or former 
employees to submit to genetic testing, 2) submit previously obtained blood samples for 
genetic testing, 3) analyze previously obtained genetic samples, 4) use any previously 
obtained genetic sample, or 5) threaten or take any adverse employment actions because of 
the legal proceedings.  Id. at *2-3. 
 126. Sismondo, supra note 110, at 475. 
 127. Fleming v. State Univ. of N.Y., 502 F. Supp. 2d 324, 327 (E.D.N.Y. 2007). 
 128. Id. at 326. 
 129. Id. at 327. 
 130. Id. 
 131. Id. 
 132. Fleming v. State Univ. of N.Y., 502 F. Supp. 2d 324, 327 (E.D.N.Y. 2007). 
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privacy under the Fourteenth Amendment, the court noted that sickle cell 
disease is a “serious medical condition,” as it exposed the plaintiff to painful 
attacks and caused the death of his sister.133  The court further described 
that knowledge of sickle cell disease “can expose an individual to 
intolerance,” as it has invoked employment and insurance discrimination 
since the 1970’s against sufferers and those who show a genetic 
predisposition to the disease.134  As such, the court held that the plaintiff’s 
right to privacy under the Fourteenth Amendment included the right to 
confidentiality with regard to his sickle cell disease.135 
Finally, in Jones v. Inter-County Imaging Centers, the plaintiff alleged 
genetic discrimination under the ADA and state human rights law.136  There, 
the plaintiff claimed that his employer, defendant Inter-County Imaging 
Center, offered him a full-time promotion but that while he was out on sick 
leave for sickle cell disease, the defendant informed him that the full-time 
position had been filled and his previous part-time position had been 
eliminated.137  The plaintiff claimed that the defendant terminated his 
employment because the Center did not want to continue to pay for the 
plaintiff’s medical costs brought on by sickle cell disease.138  While the court 
ultimately did not reach the issue of genetic discrimination,139 the plaintiff’s 
claim amounted to such an assertion. 
VI.  PRIOR NON-DISCRIMINATION EFFORTS 
Throughout the past several decades, there have been numerous 
attempts to limit genetic discrimination by state and federal legislation.  
However, such efforts have been anything but comprehensive.140  By 2008, 
forty-seven states had enacted laws prohibiting genetic discrimination in 
health insurance and thirty-five states restricted employers from adversely 
using the information against employees.141  These laws were limited, 
however, as they generally only prohibited underwriting for private health 
insurance and prohibited the use of genetic information for employment 
 
 133. Id. at 341 (citing Doe v. City of N.Y., 15 F.3d 264, 267 (2d Cir. 1994)). 
 134. Id. at 341, 343. 
 135. Id.  The court rejected the plaintiff’s ADA claim on grounds that Title II did not apply 
to employment discrimination.  Id. at 346. 
 136. Jones v. Inter-County Imaging Ctrs., 889 F. Supp. 741, 742 (S.D.N.Y. 1995). 
 137. Id. 
 138. Id. 
 139. Id. at 746 (denying the defendants’ motion to dismiss for failure to state a claim). 
 140. See Sismondo, supra note 110, at 466-67 (noting that President Clinton signed an 
executive order banning genetic discrimination in employment, but it only applied to federal 
employees). 
 141. Mark A. Rothstein, Putting the Genetic Information Nondiscrimination Act in Context, 
10 GENETICS MED. 655, 655 (2008). 
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decisions.142  Currently, no state law covers genetic discrimination from 
employer-sponsored insurance plans,143 which combine to provide the 
largest source of insurance coverage in the country.144 
While the majority of states have laws prohibiting genetic discrimination, 
they lack uniformity and “vary widely with respect to their approach, 
application, and level of protection.”145  For example, North Carolina 
requires that no “entity shall deny or refuse employment to any person or 
discharge any person from employment on account of the person’s having 
requested genetic testing or counseling services, or on the basis of genetic 
information obtained concerning the person or a member of the person’s 
family.”146  Presumably, under North Carolina law it would be permissible 
for an employer to require genetic testing as long as the information 
obtained is not used against the employee.147  There are likely very few 
appropriate reasons for such a request, and at the very least, the request 
may amount to breach of privacy and certainly opens the door for genetic 
discrimination.  Even more shocking, Florida has legislation that only 
protects people with the sickle cell trait.148  Therefore, a person’s 
predisposition to cancer—or any other illness whatsoever—would be 
acceptable grounds for discrimination. 
Before GINA, federal law also failed to adequately protect employees 
and patients from genetic discrimination.  In 1996, Congress enacted the 
Health Insurance Portability and Accountability Act (HIPAA), 149 which 
amended many provisions of the Employee Retirement Income Security Act 
of 1974 (ERISA)150 in order to better protect private health care information 
 
 142. Id. 
 143. See Sara Abiola, The Genetic Information Nondiscrimination Act of 2008: “First Major 
Civil Rights Bill of the Century” Bars Misuse of Genetic Test Results, 36 J.L. MED. & ETHICS 
856, 857 (2008) (citing National Conference of State Legislatures, Genetics and Health 
Insurance State Anti-Discrimination Laws (2008), http://www.ncsl.org/IssuesResearch/Health/ 
GeneticNondiscriminationinHealthInsuranceLaws/tabid/14374/Default.aspx). 
 144. Abiola, supra note 143, at 857 (citing Kaiser Comm’n on Medicaid & the Uninsured, 
Health Insurance Coverage in America: 2004 Data Update 10 (2005)). 
 145. GINA, Pub. L. No. 110-223, § 2, 122 Stat. 881, 882. 
 146. N.C. GEN. STAT. ANN. § 95-28.1A(a) (LexisNexis 2005). 
 147. § 95-28.1A.(a).  The statute does not prohibit employers from requiring genetic 
testing or otherwise obtaining genetic information. 
 148. See Fla. Stat. Ann. § 448.075 (West 2006) (prohibiting employers from denying or 
terminating employment because a person has the sickle-cell trait); § 448.076 (prohibiting 
mandatory testing or screening for the sickle-cell trait). 
 149. See Health Insurance Portability and Accountability Act of 1996, Pub. L. 104-191, 
110 Stat. 1936, 1936 (1996) (codified in scattered sections of 26 U.S.C., 29 U.S.C., and 42 
U.S.C.). 
 150. See Employee Retirement and Income Security Act of 1974, Pub. L. 93-406, 88 Stat. 
829 (1974) (codified at 29 U.S.C. §§ 1001-1461). 
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and address genetic discrimination.  HIPAA is a federal privacy law 
prohibiting the disclosure, and limiting the use, of confidential medical 
information.151  Before GINA, HIPAA regulations stated that “a group health 
plan . . . may not establish rules for eligibility (including continued eligibility) 
of any individual to enroll under the terms of the plan based on . . . 
[g]enetic information.”152  This section failed to prohibit the requesting or 
requiring of genetic tests, and only applied to employer-based group health 
plans.153 
HIPAA also prescribes that in the absence of a current medical 
diagnosis, the predisposition to a disease cannot be considered a 
preexisting condition for the purpose of determining issues relating to 
medical insurance.  As amended in 2006, “[g]enetic information shall not 
be treated as a condition . . . in the absence of a diagnosis of the condition 
related to such information.”154  Under HIPAA, insurance companies cannot 
use information in genetic tests to determine eligibility or set premium prices 
in employer-based or group health plans.155  However, genetic information 
could still be used to set premiums and determine eligibility for individually-
purchased plans.156  Further, nothing is mentioned about restrictions placed 
on employers.157  Because the provisions of HIPAA have left looming gaps 
 
 151. See Goldman, supra note 14, at 93 (citing Jeffrey N. Gibbs, State Regulation of 
Pharmaceutical Clinical Trials, 59 Food & Drug L.J. 265, 266 (2004)).  HIPAA is an act 
“[t]o…improve portability and continuity of health insurance coverage in the group and 
individual markets, to combat waste, fraud, and abuse in health insurance and health care 
delivery, to promote the use of medical savings accounts, to improve access to long-term care 
services and coverage, to simplify the administration of health insurance, and for other 
purposes.”  HIPAA, 110 Stat. 1936. 
 152. 29 U.S.C. § 1182(a)(1)(F) (2006). 
 153. See § 1191b(a)(1) (defining a “group health plan” as “an employee welfare benefit 
plan . . . that . . . provides medical care . . . to employees or their dependents”) (emphasis 
added). 
 154. 29 U.S.C. §1181(b)(1)(B) (2006).  Not including this specific exception for genetic 
information, section 1181(a)(1) states that “a group health plan, and a health insurance issuer 
offering group health insurance coverage, may, with respect to a participant or beneficiary, 
impose a preexisting condition exclusion only if – (1) such exclusion relates to a condition 
(whether physical or mental), regardless of the cause of the condition, for which medical 
advice, diagnosis, care, or treatment was recommended or received within the 6-month 
period ending on the enrollment date.”  29 U.S.C. §1181(a)(1). 
 155. § 1182(b) (prohibiting group health plans from charging any person a higher 
premium based on “any health status-related factor,” compared to a “similarly situated 
individual enrolled in the plan”). 
 156. Such plans fall outside the scope of the HIPAA protections discussed.  See infra notes 
169 and 172. 
 157. See generally 29 U.S.C. §§ 1181-82 (applying only to group health plans and 
“health insurance issuer[s] offering group health insurance coverage”). 
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in private insurance plans and employment decision regulations, the breadth 
of this Act does not adequately prevent genetic discrimination. 
While the Americans with Disabilities Act (ADA) has been cited in genetic 
discrimination cases, it was not enacted for that purpose and therefore gives 
little protection in the workplace.  The following excerpt summarizes the 
influence of the ADA on genetic discrimination: 
The ADA states that “[n]o covered entity shall discriminate against a 
qualified individual with a disability because of the disability of such 
individual in regard to job application procedures, the hiring, advancement, 
or discharge of employees, employee compensation, job training, and other 
terms, conditions, and privileges of employment.”  Thus, to pursue a genetic 
discrimination claim under the ADA, genetic traits must fall within the ADA’s 
definition of disability.  To be considered a disability under the ADA, a 
genetic trait must be “a physical or mental impairment that substantially 
limits one or more of the major life activities[;] . . . a record of such 
impairment; or . . . being regarded as having such an impairment.”  Since 
genetic traits tend to cause impairment in the future, the United States 
Supreme Court has suggested that genetic traits do not sufficiently meet the 
interpreted requirement that a disability be currently present.  Consequently, 
genetic traits likely fall outside of the ADA’s definition of disability.158 
Because the definition of “disability” requires that impairments have 
substantial limits on life activities, it would be difficult to prove that an 
employer acted adversely based on a person’s genetic information without 
some outward showing of symptoms.159  Thus, a genetic predisposition to a 
disease would fall outside of the scope of “disability” and discrimination 
under the ADA.  Similar to HIPAA, the ADA left too much room for “lawful” 
genetic discrimination and is still too broad to adequately protect 
employees.160 
Other genetic discrimination claims have been founded under Section 
504 of the Rehabilitation Act.161  The Rehabilitation Act states that “[n]o 
 
 158. Paul D. Trumble, “Knickel” and Dime Issues: An Unexplored Loophole in New York’s 
Genetic Discrimination Statute and the Viability of Genetic Testing in the Sports Employment 
Context, 70 ALB. L. REV. 771, 777 (2007) (internal citations omitted).  See also Americans with 
Disabilities Act, 42 U.S.C. § 12112(a) (2006). 
 159. Jeremy A. Colby, An Analysis of Genetic Discrimination Legislation Proposed by the 
105th Congress, 24 AM. J.L. & MED. 443, 466-67 (1998). 
 160. See id. at 467 (concluding that the ADA offers little protection in the absence of a 
favorable judicial interpretation).  See also, Sismondo, supra note 110, at 467 (noting the 
ADA’s broad language, its failure to expressly cover genetic discrimination, and the absence 
of any court decision recognizing that it extends to genetic information). 
 161. See, e.g., Fleming v. State Univ. of N.Y., 502 F. Supp. 2d 324, 334-39 (E.D.N.Y. 
2007) (holding that the plaintiff stated a valid claim under section 504 of the Rehabilitation 
Act after the plaintiff was allegedly constructively terminated after his employer discovered he 
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otherwise qualified handicapped individual . . . shall, solely by reason of her 
or his disability, be excluded from participation in, be denied the benefits of, 
or be subjected to discrimination under any program or activity receiving 
Federal financial assistance.”162  The major limitation of the Rehabilitation 
Act is obvious; only employees of federally funded institutions or programs 
are protected from genetic discrimination.163 
Finally, the Fourteenth Amendment has been used as a vehicle for 
genetic discrimination claims.  Plaintiffs may claim that genetic 
discrimination is a breach of privacy under the Fourteenth Amendment and 
hold the defendant liable under 42 U.S.C. § 1983.164  Section 1983 states 
that an action can be brought against any “person who, under color of any 
statute, ordinance, regulation, custom, or usage, of any State . . . subjects, 
or causes to be subjected, any citizen of the United States or other person 
within the jurisdiction thereof to the deprivation of any rights, privileges, or 
immunities secured by the Constitution and laws.”165  This claim is likely 
centered on a broad argument of privacy and, similar to the other failed 
non-discrimination efforts, it is not specific enough to entirely shield against 
many types of genetic discrimination. 
Although state laws, ERISA, HIPAA, the ADA, the Rehabilitation Act, and 
the Fourteenth Amendment have allowed for some protection against 
genetic discrimination in employment and the insurance industry, such an 
inconsistent and broad assembly of legislation has failed to adequately 
address specific cases of genetic discrimination.  Finally, in 2008, Congress 
responded to earlier legislative short-comings and adopted the Genetic 
Information Nondiscrimination Act of 2008 as the primary vehicle to 
combat genetic discrimination. 
 
had sickle cell anemia).  See also supra notes 127-35 and accompanying text (discussing 
Fleming). 
 162. Rehabilitation Act of 1973, Pub. L. 93-112, § 504, 87 Stat. 355, 394 (codified at 29 
U.S.C. § 794(a) (2006)). 
 163. See 29 U.S.C. § 794(d) (“The standards used to determine whether this section has 
been violated in a complaint alleging employment discrimination…shall be the standards 
applied under…the Americans with Disabilities Act of 1990…, as such sections relate to 
employment.”); See also Fleming, 502 F.Supp.2d at 334-37 (finding the ADA’s prohibition of 
discrimination based on medical examinations and inquiries applicable in an employment 
discrimination case under the Rehabilitation Act). 
 164. See U.S. CONST. amend. XIV, § 1 (“No State shall make or enforce any law which 
shall abridge the privileges or immunities of citizens of the United States; nor shall any State 
deprive any person of life, liberty, or property, without due process of law; nor deny to any 
person within its jurisdiction the equal protection of the laws.”). 
 165. 42 U.S.C. § 1983 (2006). 
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VII.  THE GENETIC INFORMATION NONDISCRIMINATION ACT OF 2008 (GINA) 
Congress has long been aware of genetic discrimination and its 
negative impact on genetic research participant recruitment.166  
Congresswoman Louise Slaughter (D, NY) introduced the first genetic non-
discrimination bill in the 104th Congress in 1995, and similar bills were 
introduced in the 105th, 106th, 107th, 108th, and 109th Congresses.167  
Finally, after thirteen years, the Genetic Information Nondiscrimination Act 
of 2008 was signed into law by President Bush on May 21, 2008 during the 
110th Congress.168  The Act brings much needed and anticipated uniformity 
to the prohibition of genetic discrimination in employment and health 
insurance.  To prohibit discriminatory uses of genetic information in making 
employment and health insurance decisions, GINA amends previous federal 
legislation, including ERISA, the Public Health Service Act (PHSA), the 
Internal Revenue Code of 1986, and Title XVIII of the Social Security Act 
(SSA).169  It also seeks consistency with Title VII of the Civil Rights Act of 
1964, HIPAA, and the ADA.170  While GINA provides more consistent and 
 
 166. Kathy L. Hudson et al., Keeping Pace with the Times – The Genetic Information 
Nondiscrimination Act of 2008, 358 NEW ENG. J. MED. 2661, 2662 (2008) (quoting 
cosponsor Senator Ted Kennedy: “Discrimination in health insurance and the fear of potential 
discrimination threaten both society’s ability to use new genetic technologies to improve 
human health and the ability to conduct the very research we need to understand, treat, and 
prevent genetic disease”). 
 167. H.R. REP. NO. 110-28, pt. 1, at 23 (2007). 
 168. See GINA, Pub. L. No. 110-233, 122 Stat. 881, 881, 922 (2008). 
 169. See GINA § 101, 122 Stat. at 883-88 (amending ERISA); § 102, 122 Stat. at 888-
96 (amending the PHSA); § 103, 122 Stat. at 896-99 (amending the I.R.C.); § 104, 122 Stat. 
at 899-903 (amending the SSA).  Many provisions of Title I and II look strikingly similar to the 
consent order/settlement agreement in EEOC v. Burlington Northern & Santa Fe Railway Co., 
No. 02-C-0456, 2002 WL 32155386, at *3 (E.D. Wis. 2002).  There, as part of equitable 
relief, the court prohibited Burlington Northern from requiring or requesting genetic testing 
from current or former employees or threatening adverse employment actions based on 
genetic test results.  Id. 
 170. See, e.g., H.R. REP. NO. 110-28, at 35 (“As a guiding principle, [GINA] is designed 
to extend to individuals in the area of genetic discrimination the same procedures and 
remedies as are provided under Title VII of the Civil Rights Act of 1964.”).  Provisions 
regarding the confidentiality of genetic information are “intended to be consistent with the 
ADA’s requirements regarding the maintenance and treatment of medical information.”  H.R. 
REP. NO. 110-28, at 35.  H.R. REP. NO. 110-28, at 67 (noting attempts to resolve a conflict 
between GINA and HIPAA regarding the types of information “that can be permissibly shared 
between HIPAA covered entities”).  See also Civil Rights Act of 1964, Pub. L. 88-352, 78 Stat. 
241, 253 (1964) (codified as amended at 42 U.S.C. §§ 2000e-2000e-17 (2006)); HIPAA, 
Pub. L. 104-191, 110 Stat. 1936, 2073 (1996); Americans with Disabilities Act, 42 U.S.C. §§ 
12101-12213 (2006). 
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universal non-discrimination protection, it does not preempt more protective 
state genetic non-discrimination legislation.171 
GINA is divided into two titles: Title I prohibits discrimination in health 
insurance and Title II prohibits discrimination in employment.  Under Title I, 
GINA prohibits all health insurers from using genetic information as a 
means of setting eligibility or premiums, and from requesting or requiring 
genetic tests.172  Genetic information with respect to any individual is 
defined as “information about such individual’s genetic tests, the genetic 
tests of family members of such individual, and the manifestation of a 
disease or disorder in family members of such individual.”173  Genetic test is 
defined as “an analysis of human DNA, RNA, chromosomes, proteins, or 
metabolites, that detects genotypes, mutations, or chromosomal 
changes.”174  These provisions include genetic information and testing with 
respect to the insured’s dependants, or any other first-degree, second-
degree, third-degree, or fourth-degree relatives.175 
Title II of GINA restricts employers from using genetic information to 
make employment decisions and also restricts them from requesting, 
purchasing, or requiring genetic information about a prospective employee, 
current employee, or the employee’s family members.176  These restrictions 
also apply to employment agencies, labor organizations, and those in 
charge of job training programs.177 
VIII.  LEGISLATION LIMITATIONS AND RACIAL DISPARITY 
Unfortunately, the reading of GINA’s plain text may result in unintended 
consequences.  With regard to health insurance, because GINA does not 
allow health insurers to request or require genetic tests, some individuals 
may not receive medical coverage and treatment in dangerous situations.178  
Similarly, this same prohibition does not allow health insurers to recommend 
a genetic test for preventive screening, confirming a medical diagnosis, or 
 
 171. See Abiola, supra note 143, at 856. 
 172. GINA, Pub. L. No. 110-233, §§ 101(a)-101(b), 122 Stat. 881, 883-85 (2008).  See 
also Hearing, supra note 106, at 44 (“The bill would explicitly allow researchers, for the first 
time, to tell research participants that it is simply against the law for health insurers or 
employers to use genetic information to discriminate.”). 
 173. GINA, Pub. L. No. 110-233, § 101(d), 122 Stat. at 885-86. 
 174. § 101(d), 122 Stat. at 885-86. 
 175. §§ 101(a)(3), 101(b), 122 Stat. at 883. 
 176. §§ 202(a)-(b), 122 Stat. at 907. 
 177. §§ 204-06, 122 Stat. at 910-14. 
 178. H.R. REP. NO. 110-28, pt. 1, at 66-67 (2007) (giving the example of a patient with 
hepatitis C: some viral genotypes require longer treatment and unless the health insurer 
requests a genetic test to determine the genotype, the patient may not receive adequate 
therapy). 
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predicting a response to therapy (which consequently is the major goal of 
PGx).179  These consequences could become significant obstacles to health 
insurers’ access to medical information, and in effect, patients’ access to 
care.180  In employment, the minority view of Republicans on the Committee 
on Education and Labor was that Title II could lead to an increase in 
frivolous lawsuits against employers due to the availability of punitive and 
compensatory damages.181  The minority view of the Committee on Energy 
and Commerce cites a more general problem.  Title II, the Committee 
claims, is too broad and sweeping in that it reaches practically every entity, 
corporation, foundation, and agency that has contact with employees.182 
Extending beyond GINA’s possible unintended consequences, the 
legislation has another and likely more crucial limitation in achieving its 
legislative aim.  The purpose of GINA is to “establish[ ] a national and 
uniform basic standard . . . to fully protect the public from discrimination 
and allay their concerns about the potential for discrimination, thereby 
allowing individuals to take advantage of genetic testing, technologies, 
research, and new therapies.”183  The question remains: will GINA 
encourage and allow individuals to participate in PGx research and clinical 
opportunity?  Likely, GINA has somewhat quelled the genetic discrimination 
“fear factor” when it comes to patients’ decisions about participating in 
genetic research and having the results attached to them for the rest of their 
lives.  However, in order to gain the full benefits of PGx research and its 
applications, Congress and the research communities may need to realize 
that the fear of genetic discrimination is not the only “fear factor” patients 
and individuals face.  Further, with the specific need for genotypically 
diverse minority populations, there may be a much more significant hurdle 
to fully realizing the scope of PGx than the fear of genetic discrimination. 
While genetic discrimination may be unique to genetic research, it is not 
the only risk participants and patients associate with general clinical 
research.  Risk is defined as “the chance of injury, damage, or loss”184 and 
is mostly subjective, formed through psychological, social, emotional, 
 
 179. H.R. REP. NO. 110-28, at 67. 
 180. H.R. REP. NO. 110-28, at 67. 
 181. H.R. REP. NO. 110-28, at 67-68. 
 182. See H.R. REP. NO. 110-28, pt. 3, at 66-67 (2007).  “Title II [of GINA] . . . covers 
employers from the FBI to NASA to laboratories, to State and local governments, to nuclear 
power plants, to hospitals, and many more.  Title II restricts information flow in numerous 
settings from employers involved in responses to pandemic flu outbreaks, to employers 
involved in judicial proceedings, to health and safety monitoring, and to employers 
administering or sponsoring benefits.  We cannot today easily imagine all of the 
circumstances.”  H.R. REP. NO. 110-28, at 66. 
 183. GINA, Pub. L. No. 110-233, § 2, 122 Stat. 881, 882-83 (2008). 
 184. Slovic, supra note 8, at 62 (citation omitted). 
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cultural, and political means.185  Whether the risk is real or subjective, the 
fear of such risk is absolutely real, and with respect to genetic research, 
Americans likely perceive numerous social and psychological risks that go 
well beyond genetic discrimination.186  These risks include the fear of 
learning harmful genetic information about oneself, the risk that the learning 
genetic information may have a negative impact on genetically related 
family members, the fear that genetic testing is too risky and confusing, as 
well as numerous others.187  Thus, these perceived risks should not be 
overlooked by the research community as hurdles to furthering genetic 
research and PGx participation.188 
The receipt of genetic information can be psychologically harmful to 
research and clinical participants in several ways.189  Simply learning that 
one is predisposed to a genetic disease or is certain to become afflicted with 
a disease in the future can be injurious to one’s overall well-being.190  Such 
information is likely to cause worry and be emotionally upsetting either 
because it makes the participant’s future uncertain, or because it makes it 
firmly certain.191  Additionally, a participant’s predisposition to certain 
diseases is measured in probabilities; therefore the prediction will not come 
to fruition in many cases, causing some to worry that they will waste 
valuable time and energy worrying for no reason.192  Some people even 
report that they would rather just not know about their genetic make-up than 
learn that they have a genetic predisposition to a certain disease or 
cancer.193 
 
 185. See id. at 67 (“Recent studies have shown that factors such as gender, race, political 
worldviews, affiliation, emotional affect, and trust are strongly correlated with risk 
judgments.”). 
 186. See Schoonmaker & Williams, supra note 3, at 22-25 (discussing how genetic 
information and testing can lead to many undesired outcomes). 
 187. Id. at 23-24 (stating that two additional fears include the fear of being convicted of a 
crime, and the fear of discovering that the person tested is not actually the biological relative 
of a family member). 
 188. See generally Slovic, supra note 8, at 60 (discussing that research participants and 
researchers often have differing views of risk and therefore people are generally not swayed by 
researchers’ recitations of risk statistics). 
 189. See Henderson et al., supra note 2, at 196 (noting that concerns about genetic 
research included “knowing too much,” “knowing what conditions we [have to face],” 
“realizing there is no treatment or prevention,” and “worrying”). 
 190. See DEP’T OF HEALTH & HUMAN SERV., Office for Human Research Protections, 
Institutional Review Board Guidebook, Chapter V, http://www.hhs.gov/ohrp/irb/irb_chapter 
5ii.htm#h12 (last visited March 12, 2010). 
 191. See id. 
 192. See id. 
 193. See Henderson et al., supra note 2, at 196. 
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Family plays a definite role in genetic research risk.  A recent literature 
review of studies found that people with a family history of a genetic disease 
consented to participate in genetic research at lower overall rates.194  
Logically, the lower consent rate may correspond to the participants’ fears of 
learning genetic information about themselves.  Learning one’s own 
predisposition to a disease, genotype variation, or disease marker can be 
equally detrimental to family members’ well-being, especially if the genetic 
information can be inherited.195 
Because of the significant importance of including ethnically and racially 
diverse groups in PGx research, it is crucial to understand the unique 
perceived risks that these populations face in genetic research.  This 
importance stems from the fact that minority populations are often 
underrepresented in clinical drug trials compared to the surrounding 
community.196  One researcher found that out of thirteen studies of drug 
efficacy and safety of hypertensive drugs, only eight had at least one African 
American.197  Making participation even more difficult is that as a group, 
African Americans have been found to have less positive views about 
genetic research than Caucasians.198  Several empirical studies have 
supported that African-American and ethnic minorities are less likely to 
consent to genetic testing.199  In one study, as compared to whites, African-
American and Hispanic participants reported significantly higher levels of 
 
 194. Rene Sterling, et al., Public Willingness to Participate in and Public Opinions About 
Genetic Variation Research: A Review of the Literature, 96 AM. J. PUB. HEALTH 1971, 1976 
(2006). 
 195. See SCHOONMAKER & WILLIAMS, supra note 3, at 23-24. 
 196. Noah, supra note 7, at 225-26 (discussing that in a 1989 analysis of clinical trials, 
African Americans were underrepresented in twenty-three out of thirty-five clinical trials for 
which racial data was available). 
 197. Id. at 226. 
 198. Henderson et al., supra note 2, at 196; see generally Slovic, supra note 8, at 76 
(discussing that, compared with white males, “nonwhite men see the world as more dangerous 
because in many ways they are more vulnerable, because they benefit less from many of its 
technologies and institutions, and because they have less power and control over what 
happens in their communities and their lives”). 
 199. See, e.g., Hillary R. Bogner et al., Personal Characteristics of Older Primary Care 
Patients Who Provide a Buccal Swab for Apolipoprotein E Testing and Banking of Genetic 
Material: The Spectrum Study, 7 CMTY. GENETICS 202, 207 (2004) (finding that “patients 80 
years and older and African-Americans were less likely to provide a buccal swab than other 
older patients”; Geraldine M. McQuillan et al., Consent for Genetic Research in a General 
Population: The NHANES Experience, 5 GENETICS MED. 35, 37 (2003) (finding that the lowest 
consent rates for genetic research were provided by non-Hispanic blacks); Patricia G. 
Moorman et al., Racial Differences in Enrollment in a Cancer Genetics Registry, 13 CANCER 
EPIDEMIOLOGY BIOMARKERS & PREVENTION 1349, 1349 (2004) (finding much lower enrollment 
rates for African-American women in a cancer genetics registry). 
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fear of racial discrimination than European Americans.200  The same study 
showed that African Americans reported a higher percentage of concern of 
unequal economic access to benefits.201  Also, a smaller percentage of 
African Americans named the prevention and treatment of disease as a 
perceived benefit of genetic research.202 
Trust is likely one of the most important risk barrier between African-
American participants and genetic research.  According to a recent survey, 
the rate of mistrust among African Americans as compared to whites is 
staggering.  A survey population comprised of 527 African Americans and 
382 whites was polled to examine racial differences regarding distrust of 
research and the medical community, wherein “distrust” was defined as 
“lack of agreement with a statement of trust.”203  The survey revealed that 
African Americans are less likely to trust that their physician would fully 
describe research participation, less likely to believe that they could freely 
ask their physician questions, more likely to disagree that their physician 
would not ask them to participate in research if the physician thought there 
was harm, more likely to believe that their physician exposed them to 
unnecessary harm, and more likely to believe that someone like them would 
be used as a guinea pig without his or her consent.204  The results also 
showed that a higher percentage of African-American participants believed 
that physicians have prescribed medication or given them treatment as a 
way of experimenting on them without their consent.205  The authors of the 
study concluded that past and present racial experiences may contribute 
significantly to African Americans’ mistrust of the medical and research 
community.206 
There are several reasons for African Americans’ mistrust of medicine 
and research, many of which seemingly stem from historically unequal 
treatment.  Slaves were sometimes forced into roles as research subjects so 
 
 200. Benjamin R. Bates et al., Warranted Concerns, Warranted Outlooks: A Focus Group 
Study of Public Understandings of Genetic Research, 60 SOC. SCI. & MED. 331, 335 (2005) 
(“Participants were 58 African Americans, 26 European Americans, and 7 Hispanics.”). 
 201. Id. at 336.  11.5% of African Americans were concerned about unequal economic 
access to benefits, as compared to 8.6% of European-Americans and 3.8% of Hispanic-
Americans.  Id. 
 202. Id at 339.  Only 67% of African Americans reported that the prevention and 
treatment of genetic diseases is a benefit to genetic research, while 81.8% of European-
Americans reported the same.  Id. 
 203. See Corbie-Smith et al., supra note 9, at 2459. 
 204. Id.at 2460.  See also Giselle Corbie-Smith et al., Attitudes and Beliefs of African 
Americans Toward Participation in Medical Research, 14 J. GEN. INTERNAL MED. 537, 539-40 
(1999) [hereinafter Attitudes and Beliefs] (discussing that African-American participants to 
another survey reported fear of being used as “guinea pigs” and “being experimented on”). 
 205. See Corbie-Smith et al., supra note 9, at 2460. 
 206. See id. at 2462. 
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that researchers could study sunstroke, surgical techniques, and postmortem 
dissection.207  Further, the infamous Tuskegee study has helped continue the 
trend of mistrust in recent decades.208  Even though some potential African-
American research participants have inaccurate knowledge about the study, 
many have nonetheless referenced the study as a reason for researcher 
mistrust.209  Regardless of the accuracy of their beliefs, their version of the 
study is what they believe to be “real.”210  Some African Americans even 
believe that a government conspiracy was to blame for the results of the 
Tuskegee study and that such a conspiracy exists to this day and is 
responsible for introducing HIV into the African-American community.211  
Even more daunting for PGx research in particular is that African Americans 
report the highest levels of mistrust in studies and trials involving the 
collection of DNA.212 
State legislation has also helped fuel historical mistrust.  In the 1970’s, 
some states enacted laws requiring African Americans to undergo genetic 
tests indicating markers for sickle cell anemia.213  Such laws heightened 
racial discrimination and scrutiny.214  Whatever the reason may be for 
mistrust among various African-American communities and individuals, 
without trust, no level of communication between researchers and African-
American participants may be adequate for research recruitment.  In other 
words, if the African-American participant does not trust the research and 
medical community, he or she may not trust the researchers’ positive 
assertions about genetic research, its benefits, or its minimal risk, and 
therefore may not participate. 
Other risks and barriers to minority recruitment for genetic research exist 
and should not be ignored.  Such factors include financial barriers, attitudes 
of treating physicians, pharmaceutical company involvement, and health 
illiteracy.215  Further, while it is not a perceived risk per se, a certain barrier 
 
 207. Noah, supra note 7, at 229. 
 208. See id. at 229-30.  Participants of the study included 400 African Americans who 
were believed to have syphilis.  The study was designed to investigate the natural development 
of the disease over time.  When the study began in the 1930s, there was no known cure for 
syphilis.  However, once penicillin was discovered to be an effective treatment, the 
investigators failed to inform the study participants that there was a cure.  Id. 
 209. See Attitudes and Beliefs, supra note 204, at 543. 
 210. Id. 
 211. Noah, supra note 7, at 230. 
 212. See Cathrine Hoyo, Barriers and Strategies for Sustained Participation of African-
American Men in Cohort Studies, 13 ETHNICITY & DISEASE 470, 472 (2003). 
 213. GINA, Pub. L. No. 110-233,§ 2, 122 Stat. 881, 882 (2008) (codified at 26 U.S.C., 
29 U.S.C. § 2000ff). 
 214. § 2, 122 Stat. at 882.  In response, Congress passed the National Sickle Cell Anemia 
Control Act, Pub. L. No. 92-294, 86 Stat. 136-39 (1972). 
 215. See Noah, supra note 7, at 226-28. 
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to African-American research participation is lack of scientific and medical 
understanding.216  Unfortunately, this barrier is confounded by the 
presumption that race is correlated with lower socio-economic status and 
education, both of which correlate with lower health status.217 
IX.  ADDRESSING RACIAL DISPARITIES IN PGX RESEARCH AND CLINICAL 
OPPORTUNITY 
In order for PGx to reach its full potential, African-American populations 
must be included in clinical drug trials so that the link between race and 
genetic variation can be better understood.  Only then can this population 
benefit from the clinical applications of PGx research.  In order for this to 
occur, however, more focus must be placed on identifying risks important to 
the specific study population, and on educating the public about risks and 
their truthful relation to genetic research.  While numerous methods for 
achieving this goal have been suggested, many scholars support some form 
of “community-based review” as a useful vehicle for public education.218  
Community review involves aspects of “community approval, group consent, 
communal discourse, and other methods of consulting with communities 
about the potential implications of genetic research.”219 
From the researchers’ perspective, community involvement will help form 
a long-term relationship and allow researchers to better understand risks 
facing the research participants.220  Specifically, constructive dialogue can 
identify both perceptions of PGx and the public’s willingness to participate in 
clinical research.221  Such a dialogue has begun with regard to African 
Americans’ views on ways to improve participation in research.222  
Participants of the dialogue “expressed the need for more honest and 
respectful communication from physicians and other research personnel, 
and the importance of providing complete information about risk and 
benefits of research.”223  The participants of this survey also suggested it 
would be beneficial to have time to research the study implications on their 
own and talk to family and friends about such implications.224  Further 
suggestions included more education and promotion of awareness of the 
 
 216. Id. at 228. 
 217. Id. at 229. 
 218. See e.g., Richard R. Sharp & Morris W. Foster, Involving Study Populations in the 
Review of Genetic Research, 28 J.L. MED. & ETHICS 41, 42 (2000). 
 219. Id. (noting that “[i]n its least demanding form, community review could be little more 
than informal dialogue between researchers and members of the study population”). 
 220. Id. 
 221. See HHS, supra note 10, at 8. 
 222. See Attitudes and Beliefs, supra note 204, at 541. 
 223. Id. 
 224. Id. 
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purpose of research.225  Once researchers fully understand the cultural 
values and perceived risks and attitudes toward genetic research, they can 
create community-tailored recruitment strategies and research designs. 
Because researcher and physician mistrust is one of the most cited 
barriers to minority research participation, establishing cultural trust must be 
a primary objective of community review.  Researcher knowledge and 
participant mistrust are inevitably intertwined, and as such, building trust 
should include all facets of community involvement, such as engagement, 
dialogue, and feedback.226  Based on information from African-American 
participants, one study suggested identifying civil organizations in the 
community, the head of which could operate as a “gate keeper” between 
the researcher and possible participants.227  In this model, “clusters” of 
participants would be identified within the civic organizations and the 
gatekeeper of the organization would approach individuals in the cluster 
about research participation.228  Recommended civic organizations included 
churches, fraternity and sorority organizations at Historically Black Colleges 
and Universities (HBCU), Partners Against Crime, various women’s 
organizations, and the American Legion.229  The study also suggested that 
African-American trust would increase if the researchers themselves were 
African American.230 
Researchers should be cautious, however, not to offend or alienate 
minority participants, as differing experiences have left many African 
Americans vulnerable.  In opening a community dialogue, researchers 
should be careful not to label individuals as belonging to a particular group 
or base their discussions on an assumption that all members of the group 
have the same concerns and beliefs.231  Additionally, researchers should 
ensure that any conversations take the form of a dialogue, such that there is 
the ability for questions and answers, as opposed to a monologue where the 
researcher gives a convoluted “presentation” of research benefits and 
risks.232  With such careful consideration and assessment, genetic research 
participation risks and barriers can be identified and addressed in order that 
PGx can bring safe and effective medicine to the entire American 
population. 
 
 225. Id. at 542. 
 226. See Corbie-Smith et al., supra note 9, at 2462. 
 227. Hoyo, supra note 212, at 473. 
 228. See id. 
 229. See id. at 473-74. 
 230. Id. at 474. 
 231. See Noah, supra note 7, at 230-31. 
 232. See id. 
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X.  CONCLUSION 
Researchers, pharmaceutical companies, and scholars agree that PGx 
has the potential to greatly impact the future of medicine by producing safe, 
efficient, and cost-effective drugs.  With continued increases in research 
participation and public interest among diverse racial, ethnic, and genetic 
backgrounds, the long-terms goals of PGx research will likely be exceeded. 
GINA has certainly allowed research to continue its forward progress by 
alleviating or reducing participants’ fears of genetic discrimination by 
insurance companies and employers.  This federal law was greatly needed 
to add consistency to fragmented state laws and give more severe penalties 
to those employers and insurers who discriminate against research 
participants. 
However, the failure of legislation to recognize the numerous other 
psychological and social risks associated with genetic research in the 
African-American community will thwart the forward progress of PGx 
research and implementation.  While GINA has taken a substantial step 
forward in eliminating genetic discrimination and thus calming some of the 
American public’s fears, PGx research will only reach its full clinical 
potential when other risks are clearly identified and addressed through 
various forms of community review and involvement. 
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